CJC-1295 No DAC
10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.
$139.99
DetailsHover to zoom
Growth Hormone ResearchSynthetic GHRH analog with drug affinity complex
CJC-1295 w/DAC
$79.99
5 mgCJC-1295 with DAC is a modified GHRH (1–29) analog carrying a maleimido-propionic acid group — the Drug Affinity Complex — that binds covalently to serum albumin in preclinical models.
That binding substantially extends its circulating half-life, so it is used in laboratory research where sustained GHRH receptor engagement across long experimental time courses is required.
Research areas
GHRH receptor signalingPeptide half-life researchAlbumin-binding chemistryPreclinical research
Form: Lyophilized (freeze-dried)
- Compound class
- Synthetic GHRH analog with drug affinity complex
- Research category
- Growth Hormone Research
- SKU
- NVR-CJC-1295-WITH-DAC-5MG
- Alternate name
- CJC DAC
- CAS
- 863288-34-0
- Appearance
- White lyophilized powder
- Storage
- Store lyophilized at −20 °C. Protect from light and moisture.
Research use only
Strength
5 mg$79.99$16.00/mg
1
$79.99per 5 mg$16.00/mg
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Research Grade
Batch Documentation
Research Use Only
U.S.-Based Fulfillment
What you should know
More detail on CJC-1295 w/DAC.
Analytical values reflect per-lot documentation and appear once a batch is released.
Compound
Albumin conjugation is a well-established strategy for extending peptide duration, and CJC-1295 with DAC is a frequently cited example applied to the GHRH scaffold. The DAC modification reacts with a free thiol on serum albumin, effectively converting a rapidly cleared peptide into a long-lived one. Research applications include comparing sustained versus pulsatile GHRH receptor stimulation, studying receptor desensitization, and evaluating albumin-binding chemistry as a general half-life extension approach. All such work is preclinical.
Peptide class
Synthetic GHRH analog with drug affinity complex
Mechanism (research context)
The DAC modification enables reversible covalent attachment to circulating serum albumin in preclinical models, substantially extending functional exposure relative to unmodified CJC-1295.
Why it is studied
This variant provides a long-acting GHRH-analog research tool useful for pharmacokinetic-modeling studies and experiments requiring extended receptor exposure.
Current areas of research
GHRH receptor signalingPeptide half-life researchAlbumin-binding chemistryPreclinical research
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
Scientific background
The drug affinity complex approach was developed to extend peptide half-life by leveraging serum albumin as a natural carrier. CJC-1295 with DAC is one of the most cited applications of this technology in the somatotropic literature.
Its extended in-model activity distinguishes it from the no-DAC variant and from native GHRH.
Related
View all →Related research materials
CJC-1295 No DAC / Ipamorelin
5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.
$59.99
DetailsGHRP-2 Acetate
10 mg
Second-generation growth hormone releasing peptide studied as a ghrelin receptor agonist reference.
$39.99
DetailsGHRP-6 Acetate
10 mg
Early growth hormone releasing hexapeptide widely cited as a ghrelin receptor research standard.
$39.99
DetailsCJC-1295 w/DAC
5 mg · $79.99